Bio-Rad - Preparing for a Stress-free QC Audit

LSBio acquires Absolute Antibody

Seattle, US-based LSBio, a leading provider of antibodies and life science research reagents, has acquired UK-based Absolute Antibody and its sister company Kerafast. Terms of the transaction were not disclosed.

LSBio provides IHC-validated reagent antibodies and services to the global community of acaemic, pharmaceutical and biotech researchers. The Company has built a catalogue of more than 750,000 reagent antibodies, assay kits, proteins, and biochemicals, and its acquisition of Absolute Antibody and Kerafast further expands its product portfolio by adding a range of unique reagents and antibody services.

Absolute Antibody specializes in recombinant antibody technology, offering antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalogue of recombinant antibodies and Fc Fusion proteins, engineered into new and useful formats. In 2018, Absolute Antibody merged with Kerafast Inc., a Boston-based company that facilitates access to unique laboratory-made reagents, to further the availability of recombinant antibodies. The new acquisition combines a strong recombinant antibody portfolio with LSBio’s expertise in application-specific validation to make sequence-defined, reproducible antibodies more widely available for IHC and other key research applications.

The acquisition marks the latest investment by LSBio to rapidly build its product portfolio.

In 2019, LSBio acquired both Nordic-MUbio and Everest Biotech to strengthen the Company’s offering of proprietary monoclonal and polyclonal antibodies. All LSBio companies currently retain their independent names, websites and employees, with the entire family of companies owned by St. Louis-based private equity firm Thompson Street Capital Partners.